160 related articles for article (PubMed ID: 8978310)
1. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Mapara MY; Körner IJ; Hildebrandt M; Bargou R; Krahl D; Reichardt P; Dörken B
Blood; 1997 Jan; 89(1):337-44. PubMed ID: 8978310
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
3. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.
Mapara MY; Körner IJ; Lentzsch S; Krahl D; Reichardt P; Dörken B
Exp Hematol; 1999 Jan; 27(1):169-75. PubMed ID: 9923456
[TBL] [Abstract][Full Text] [Related]
4. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Brugger W; Henschler R; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1994 Sep; 84(5):1421-6. PubMed ID: 7520769
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
Preti RA; Lazarus HM; Winter J; Stadtmauer EA; Nadasi S; McMannis J; Karandish S; Jennis A; Goldberg SL; Pecora AL
Cytotherapy; 2001; 3(2):85-95. PubMed ID: 12028831
[TBL] [Abstract][Full Text] [Related]
6. Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukapheresis products from patients with breast cancer: comparison with immunocytochemistry.
López-Guerrero JA; Gilabert PB; González EB; Sanz Alonso MA; Pérez JP; Talens AS; Oraval EA; de la Rubia Comos J; Boix SB
J Hematother; 1999 Feb; 8(1):53-61. PubMed ID: 10192302
[TBL] [Abstract][Full Text] [Related]
7. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G; Sniecinski I; Odom-Maryon T; Nowicki B; Chow W; Hamasaki V; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Tetef M; Molina A; Berenson RJ; Forman SJ; Doroshow JH
Blood; 1997 Mar; 89(5):1521-8. PubMed ID: 9057632
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection.
Tchirkov A; Kanold J; Giollant M; Halle-Haus P; Berger M; Rapatel C; Lutz P; Bergeron C; Plantaz D; Vannier JP; Stephan JL; Favrot M; Bordigoni P; Malet P; Briançon G; Deméocq F
Med Pediatr Oncol; 1998 Apr; 30(4):228-32. PubMed ID: 9473757
[TBL] [Abstract][Full Text] [Related]
9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
10. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.
Rambaldi A; Borleri G; Dotti G; Bellavita P; Amaru R; Biondi A; Barbui T
Blood; 1998 Mar; 91(6):2189-96. PubMed ID: 9490708
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
[TBL] [Abstract][Full Text] [Related]
12. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
14. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
Han X; Shi Y; Zhang W
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation.
Cancelas JA; Querol S; Canals C; Picón M; Azqueta C; Solà C; Montes A; Amill B; Griera E; Inglés J; López JJ; Germà JR; García-López J
Transfusion; 1998; 38(11-12):1063-70. PubMed ID: 9838939
[TBL] [Abstract][Full Text] [Related]
16. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
Després D; Flohr T; Uppenkamp M; Baldus M; Hoffmann M; Huber C; Derigs HG
J Hematother Stem Cell Res; 2000 Aug; 9(4):557-64. PubMed ID: 10982256
[TBL] [Abstract][Full Text] [Related]
17. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
18. Purging of tumor cells from leukapheresis products: experimental and clinical aspects.
Kvalheim G; Wang MY; Pharo A; Holte H; Jacobsen E; Beiske K; Kvaløy S; Smeland E; Funderud S; Fodstad O
J Hematother; 1996 Aug; 5(4):427-36. PubMed ID: 8877718
[TBL] [Abstract][Full Text] [Related]
19. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
[TBL] [Abstract][Full Text] [Related]
20. Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency.
Hildebrandt M; Mapara MY; Körner IJ; Bargou RC; Moldenhauer G; Dörken B
Exp Hematol; 1997 Jan; 25(1):57-65. PubMed ID: 8989908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
